Oligonucleotide Therapeutics & Delivery Conference
Apr 5 - Apr 7, 2016
CMX157, a Novel, Liver-Targeted, Tenofovir Prodrug, for the Treatment of Chronic HBV Infection
CMX157 is a novel, liver-targeted, lipid conjugate prodrug of tenofovir (TFV) designed to utilize natural lipid uptake pathways to achieve high hepatocellular levels of the active antiviral. Recent in vitro studies have shown that CMX157 and tenofovir alafenamide fumarate (TAF) were similarly potent against hepatitis B virus (HBV), with CMX157 trending toward higher potency. High plasma stability and high first-pass liver extraction are expected to result in low clinical doses, anchoring single pill antiviral combinations, decreasing circulating TFV and off-target TFV toxicities, particularly to bone and kidneys, compared to the currently licensed TFV prodrug.